Eligibility criteria
NAFLD, liver disease, NAFLD/NASH, human immunodeficiency virus, yearsCapability, α-1-antitrypsin deficiency)Liver
HEPATITIS B, HUMAN IMMUNODEFICIENCY VIRUS, VIRUS INFECTION, CHOLESTATIC LIVER DISEASE, AUTOIMMUNE DISEASES, LIVER DISEASE, DRUG-INDUCED LIVER INJURY, SECONDARY, HEREDITARY HEMOCHROMATOSIS, WILSON DISEASE, CHRONIC LIVER DISEASE
The following are the inclusion criteria:NAFLD diagnosed by (1) histologic assessment with a fat accumulation of > 5% of the liver’s weight on biopsy or (2) radiologic assessment with MRI-PDFF ≥ 8%Age between 19 and 75 yearsCapability to understand the study and the individual consequences of participationSigned and dated declaration of agreement in the forefront of the studyThe following are the exclusion criteria:Daily alcohol consumption > 30 g in men and > 20 g in womenOther causes of chronic liver disease (hepatitis B, C, D, and E virus infection; human immunodeficiency virus; autoimmune diseases; chronic cholestatic liver disease; drug-induced liver injury; hereditary hemochromatosis; Wilson disease; and α-1-antitrypsin deficiency)Liver cirrhosisHepatocellular carcinomaMedications that cause liver disease or secondary NAFLD (e.g., tamoxifen, systemic corticosteroids, methotrexate, tetracycline, estrogens, and valproic acid)Changes in body weight > 5% in the last 3 monthsIntake of medical treatment for NAFLD/NASH in the last 6 months (except vitamin E)DiabetesPregnancyPatients after organ transplantationMissing or lacking consent capability